CN116490776A - 用于检测和治疗卵巢癌的方法 - Google Patents

用于检测和治疗卵巢癌的方法 Download PDF

Info

Publication number
CN116490776A
CN116490776A CN202180073446.5A CN202180073446A CN116490776A CN 116490776 A CN116490776 A CN 116490776A CN 202180073446 A CN202180073446 A CN 202180073446A CN 116490776 A CN116490776 A CN 116490776A
Authority
CN
China
Prior art keywords
ovarian cancer
subject
das
n3ap
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180073446.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·法尔曼
S·哈纳什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN116490776A publication Critical patent/CN116490776A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CN202180073446.5A 2020-10-29 2021-10-27 用于检测和治疗卵巢癌的方法 Pending CN116490776A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107160P 2020-10-29 2020-10-29
US63/107,160 2020-10-29
PCT/US2021/056852 WO2022093960A1 (en) 2020-10-29 2021-10-27 Methods for the detection and treatment of ovarian cancer

Publications (1)

Publication Number Publication Date
CN116490776A true CN116490776A (zh) 2023-07-25

Family

ID=81383153

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180073446.5A Pending CN116490776A (zh) 2020-10-29 2021-10-27 用于检测和治疗卵巢癌的方法

Country Status (7)

Country Link
US (1) US20240044902A1 (enExample)
EP (1) EP4237090B1 (enExample)
JP (1) JP2023548110A (enExample)
KR (1) KR20230113742A (enExample)
CN (1) CN116490776A (enExample)
CA (1) CA3196725A1 (enExample)
WO (1) WO2022093960A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024020427A2 (en) * 2022-07-21 2024-01-25 Board Of Regents, The University Of Texas System Methods for the detection and treatment of ovarian cancer
KR20250017689A (ko) 2023-07-27 2025-02-04 가톨릭대학교 산학협력단 난소암 발병 위험률 예측 방법 및 분석장치

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161059A1 (en) * 2003-03-11 2007-07-12 Trans Genic Inc. N1,n12-diacetylspermine as tumor marker
US20080014211A1 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes
US20150038522A1 (en) * 2012-02-23 2015-02-05 Keio University Combined anticancer drug sensitivity-determining marker
CN105722466A (zh) * 2013-09-13 2016-06-29 癌症研究科技有限公司 生物流体过滤组件
CN105765383A (zh) * 2013-10-28 2016-07-13 唾液科技有限公司 癌症用唾液生物标记物、其测定方法、装置、以及癌症用唾液生物标记物的特定方法
US20160362434A1 (en) * 2015-06-12 2016-12-15 Brock University Methods and compounds for enhancing contrast in magnetic resonance imaging (mri)
WO2017216025A1 (en) * 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Mps-1 inhibitors
CN109870579A (zh) * 2019-02-03 2019-06-11 辽宁迈迪生物科技股份有限公司 单克隆抗体保护液及制备方法和应用、应用单克隆抗体保护液的试剂与免疫组化试剂盒
WO2019178216A1 (en) * 2018-03-13 2019-09-19 Baylor Research Institute Methods and compositions for treating, diagnosing, and prognosing ovarian cancer
US20200025766A1 (en) * 2017-02-09 2020-01-23 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2535805A1 (en) * 2003-08-15 2005-02-24 University Of Pittsburgh Of The Commnonwealth System Of Higher Education Multifactorial assay for cancer detection
CN101855553B (zh) * 2007-06-29 2014-06-11 韩国安国药品株式会社 卵巢癌的预测标记
WO2013188391A2 (en) * 2012-06-11 2013-12-19 Georgia Regents University Biomarkers for ovarian cancer
FI3478286T3 (fi) * 2016-06-29 2024-03-14 Tesaro Inc Menetelmiä munasarjasyövän hoitamiseksi
JP7272627B2 (ja) * 2019-01-24 2023-05-12 公立大学法人和歌山県立医科大学 卵巣腫瘍の評価用バイオマーカー

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161059A1 (en) * 2003-03-11 2007-07-12 Trans Genic Inc. N1,n12-diacetylspermine as tumor marker
US20080014211A1 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes
US20150038522A1 (en) * 2012-02-23 2015-02-05 Keio University Combined anticancer drug sensitivity-determining marker
CN105722466A (zh) * 2013-09-13 2016-06-29 癌症研究科技有限公司 生物流体过滤组件
CN105765383A (zh) * 2013-10-28 2016-07-13 唾液科技有限公司 癌症用唾液生物标记物、其测定方法、装置、以及癌症用唾液生物标记物的特定方法
US20160362434A1 (en) * 2015-06-12 2016-12-15 Brock University Methods and compounds for enhancing contrast in magnetic resonance imaging (mri)
WO2017216025A1 (en) * 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Mps-1 inhibitors
US20200025766A1 (en) * 2017-02-09 2020-01-23 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer
WO2019178216A1 (en) * 2018-03-13 2019-09-19 Baylor Research Institute Methods and compositions for treating, diagnosing, and prognosing ovarian cancer
CN109870579A (zh) * 2019-02-03 2019-06-11 辽宁迈迪生物科技股份有限公司 单克隆抗体保护液及制备方法和应用、应用单克隆抗体保护液的试剂与免疫组化试剂盒

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAVA PERETZ等: "Urine metabolomics reveals novel physiologic functions of human aldehyde oxidase and provides biomarkers for typing xanthinuria", 《METABOLOMICS》, 14 November 2011 (2011-11-14) *
任玉珊;韩钰;王艳林;: "多胺类似物及其抗肿瘤作用机制", 中国新药与临床杂志, no. 10, 25 October 2009 (2009-10-25) *
黄少良;赵丽;郭青龙;吴玉林;: "Hedgehog信号通路参与肿瘤耐药机制研究的最新进展", 中国药科大学学报, no. 03, 25 June 2016 (2016-06-25) *

Also Published As

Publication number Publication date
WO2022093960A1 (en) 2022-05-05
JP2023548110A (ja) 2023-11-15
KR20230113742A (ko) 2023-08-01
EP4237090A1 (en) 2023-09-06
EP4237090A4 (en) 2024-09-25
EP4237090B1 (en) 2026-02-18
US20240044902A1 (en) 2024-02-08
CA3196725A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
US20250251399A1 (en) Biomarkers for pancreatic cancer
CN108957006B (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
EP2362942B1 (en) Biomarkers
US9964542B2 (en) Bladder cancer detection composition, kit, and associated methods
CN108603887B (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
US20240159753A1 (en) Methods for the detection and treatment of lung cancer
JP2011515666A (ja) トリプルネガティブ乳がんに関連するｄｎａ修復タンパク質およびその使用法
CN103229052A (zh) 用于前列腺癌的生物标记及其使用方法
JP2016531579A (ja) 食道がんのための分子診断試験
WO2014074682A1 (en) Chronic obstructive pulmonary disease (copd) biomarkers and uses thereof
US20240044902A1 (en) Methods for the detection and treatment of ovarian cancer
US20200087733A1 (en) Biomarker for measurement of response and prognosis of triple-negative breast cancer to anticancer agent
US20180274037A1 (en) Novel biomarkers for pancreatic diseases
CN111763736B (zh) 用于诊断甲状腺乳头状癌淋巴结转移的液体活检试剂盒
CN119968213A (zh) 用于检测和治疗卵巢癌的方法
EP3295176A1 (en) Biomarkers for detection of tuberculosis risk
US20250116676A1 (en) Phosphopeptide/phosphoprotein signature predicting basal-like breast cancer recurrence
KR20260043982A (ko) 폐 선암의 조직병리학적 아형 식별 및 예후 예측을 위한 바이오마커 및 이의 용도
HK40090190A (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
KR20130086898A (ko) 유방암 환자의 화학요법제 저항성 예측을 위한 혈청 바이오마커
HK40118234A (en) Biomarkers for pancreatic cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination